Disclaimer Osteoporosis Canada Disclaimer  The information you give us is used to provide answers to your general questions about Osteoporosis and bone health. We cannot provide individualized advice.  The answers […]

2023 Clinical Practice Guideline Clinical practice guideline for management of osteoporosis and fracture prevention in Canada: 2023 update. This guideline is an update of the 2010 Osteoporosis Canada clinical practice […]

We are aware of recent press reports concerning the link between two drugs for osteoporosis (alendronate and zoledronate) and the occurrence of a heart condition characterized by an irregular heart […]

POSITION STATEMENTS POSITION STATEMENTS General Public General Public For Osteoporosis Canada’s position statements for members of the general public. VIEW HEALTHCARE PROFESSIONALS HEALTHCARE PROFESSIONALS For Osteoporosis Canada’s position statements for […]

We are aware of recent press reports concerning the link between two drugs for osteoporosis (alendronate and zoledronate) and the occurrence of a heart condition characterized by an irregular heart […]

Osteoporosis Canada is pleased to share that long-time volunteer Dr. Hilary Jaeger is one of three leaders recognized as Honorary Fellows of the Royal College for her transformative contributions to […]

Dr. Mohit Bhandari, a member of the SAC Executive committee,  a Professor in the Department of Surgery at McMaster University and a leader in the field of orthopedic surgery has […]

As a member of The Health Charities Coalition of Canada (HCCC) our organization, Osteoporosis Canada, is pleased to see federal support for the establishment of the Canadian Drug Agency which […]

This report provides a national overview on diagnosed osteoporosis, related fractures and the osteoporosis care gap among Canadians 40 years and older.  It reports on administrative data from the Canadian […]